Figure 4.

(A‐C) MaR1 increased Aβ₄₂‐uptake in d‐THP‐1 cells. Differentiated THP‐1 (d‐THP‐1) cells were incubated for 20 min with 1 μg/mL HiLyteFluor 488‐conjugated Aβ₄₂ alone together with 5 μM MaR1. Incubation with vehicle served as control. Aβ₄₂ uptake was observed by fluorescence microscopy (A) and assessed by flow cytometry (B and C). Green fluorescence can be seen inside the cells indicating the uptake of Aβ₄₂ (A). (B) shows an example of flow cytometry data from one experiment. For each treatment, one thousand gated events were analysed in the FITC‐channel. Vehicle control (black line) was considered as Aβ₄₂‐negative. A right shift of the peak was observed upon incubation with Aβ₄₂ indicating Aβ₄₂‐uptake (red line), and MaR1 treatment further increased the Aβ₄₂‐uptake (green line). Analysis of the data from ten experiments showed that MaR1 significantly increased the Aβ₄₂‐uptake in d‐THP‐1 cells (C). Analysis of variance (ANOVA) was performed with the non‐parametric Kruskal–Wallis (K‐W) test, using the built‐in post hoc test for multiple comparisons to find significant differences between treatments. *P < 0.05 vs. 1 μg/mL Aβ₄₂. Aβ = β‐amyloid; FITC = fluorescein isothiocyanate; MaR1 = maresin 1